NovaBay Pharmaceuticals, Inc. (NBY) Dividend History

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative treatments for infections and skin conditions. The company is known for its research on novel antimicrobial compounds, particularly NVC-422, targeting ocular, skin, and mucous membrane infections. NovaBay aims to provide alternatives to traditional antibiotics, with a focus on anti-infective and dermatological products.

Dividend History

NovaBay Pharmaceuticals, Inc. currently does not pay dividends

Company News

  • Impetigo Drugs Global Strategic Business Report 2024 - Fusidane Drug Segment is Expected to Reach US$883.5 Million by 2030, with a CAGR of a 5.1%

    The global impetigo drugs market is expected to grow at a CAGR of 4.5% from 2023 to 2030, driven by factors such as the increasing incidence of impetigo, technological advancements in drug delivery, and the development of new antibiotics to combat antibiotic resistance.

    GlobeNewswire Inc.
    Featured Companies: PCVX
  • NovaBay slashes prices on eyecare products for Amazon Prime Day - Investing.com

    NovaBay Pharmaceuticals is offering a 20% discount on its Avenova-branded eyecare products during Amazon Prime Day, aligning with National Dry Eye Awareness Month. The company aims to attract new and existing customers through this promotion, which comes amid growing sales of its products through online channels.

    Investing.com
    Featured Companies: AMZN
  • NovaBay reports 9% increase in eyecare revenue in 2024 - Investing.com

    NovaBay Pharmaceuticals reported a 9% increase in net revenue for its eyecare segment in the second quarter and first half of 2024, driven by strong sales of its Avenova-branded products through online channels.

    Investing.com
  • First Phase of Exploration on Foothills Property Confirms Presence of High TiO2 Grades

    MONTRÉAL, June 27, 2024 (GLOBE NEWSWIRE) -- NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is proud to announce that, following the start of exploration work on the Foothills project, assay results confirm the presence of high TiO2 grades in massive ilmenite boulders. The Foothills project is located north of Saint-Urbain, 100 km north of Quebec City and 90 km south of Saguenay (La Baie region), Quebec. The project covers an area of approximately 285 km2 and comprises five separate claim blocks. It covers most of the contact of the intrusive zone known as the Saint-Urbain anorthosite.

    GlobeNewswire Inc.
  • La première phase d’exploration sur la propriété Foothills confirme la présence de fortes teneurs en TiO2

    MONTRÉAL, 27 juin 2024 (GLOBE NEWSWIRE) -- Les Métaux NioBay inc. (« NioBay » ou la « Société ») (TSX-V: NBY) (OTCQB: NBYCF) est fière d’annoncer qu’à la suite du début des travaux d’exploration sur le projet Foothills, les résultats d’analyse confirment la présence de fortes teneurs en TiO2 dans des blocs d’ilménite massive. Le projet Foothills est situé au nord de Saint-Urbain, à 100 km au nord de la ville de Québec et à 90 km au sud de Saguenay (région de La Baie), au Québec. Le projet couvre une superficie d'environ 285 km2 et comprend cinq blocs de claims distincts. Il couvre la majeure partie du contact de la zone intrusive connue sous le nom d'anorthosite de Saint-Urbain.

    GlobeNewswire Inc.
Dividend data last updated 06/07/2025 03:50:09 UTC